53844-98-7

Usage

Uses

Used in Organic Synthesis:
2,4-Dihydroxy-5-nitrobenzaldehyde is used as a reagent in organic synthesis for its ability to participate in various chemical reactions, contributing to the formation of new compounds and materials.
Used as a pH Indicator:
2,4-Dihydroxy-5-nitrobenzaldehyde is utilized as a pH indicator due to its color-changing properties in response to different pH levels, making it useful for monitoring and measuring acidity or alkalinity in solutions.
Used in Pharmaceutical Production:
2,4-Dihydroxy-5-nitrobenzaldehyde is used as a key intermediate in the manufacturing process of certain pharmaceuticals, playing a crucial role in the development of new drugs and medications.
Used in Dye Production:
2,4-Dihydroxy-5-nitrobenzaldehyde is also employed in the production of dyes, particularly for its strong yellow color, which is valuable in the creation of colorants for various industries.
Used in Research:
2,4-Dihydroxy-5-nitrobenzaldehyde is utilized in research settings for its distinctive properties, allowing scientists to explore its potential applications and further understand its chemical behavior.

InChI:InChI=1/C7H5NO5/c9-3-4-1-5(8(12)13)7(11)2-6(4)10/h1-3,10-11H

Upstream product

• 873974-93-7 5-formyl-2,4-dihydroxybenzoic acid 
• 95-01-2 2,4-Dihydroxybenzaldehyde 
• 7664-93-9 sulfuric acid 
• 7697-37-2 nitric acid 
• 6468-19-5 2,4-dimethoxy-5-nitrobenzaldehyde 

Downstream Products

• 6468-19-5 2,4-dimethoxy-5-nitrobenzaldehyde 
• 1593841-29-2 3-(2,4-dihydroxy-5-((2E,4E)-7-methylocta-2,4-dienamido)phenyl)propanoic acid 
• 1593841-27-0 methyl 3-(2,4-dihydroxy-5-((2E,4E)-7-methylocta-2,4-dienamido)phenyl)propanoate 

Relevant academic research and scientific papers

Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy in Vivo

Two series of novel o-(biphenyl-3-ylmethoxy)nitrophenyl compounds (A1-31 and B1-17) were designed as programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) inhibitors. All compounds showed significant inhibitory activity with IC50 values ranging from 2.7 to 87.4 nM except compound A17, and compound B2 displayed the best activity. Further experiments showed that B2 bound to the PD-L1 protein without obvious toxicity in Lewis lung carcinoma (LLC) cells. Furthermore, B2 significantly promoted interferon-gamma secretion in a dose-dependent manner in vitro and in vivo. Especially, B2 exhibited potent in vivo anticancer efficacy in an LLC-bearing allograft mouse model at a low dose of 5 mg/kg, which was more active than BMS-1018 (tumor growth inhibition rate: 48.5% vs 17.8%). A panel of immunohistochemistry and flow cytometry assays demonstrated that B2 effectively counteracted PD-1-induced immunosuppression in the tumor microenvironment, thereby triggering antitumor immunity. These results indicate that B2 is a promising PD-1/PD-L1 inhibitor worthy of further development.

Nitrophenyl ether compounds, and preparation methods, pharmaceutical compositions and application thereof

The invention discloses nitrophenyl ether compounds, and preparation methods, pharmaceutical compositions and application thereof, belonging to the field of medicines. The invention particularly relates to the nitrophenyl ether compounds with structural c

Convergent synthesis of Carpatamide-A: Cytotoxic arylamine derivative from marine derived Streptomyces sp.

First total synthesis of carpatamide-A 7a, cytotoxic arylamine derivative isolated from marine derived Streptomyces sp., was achieved in twelve steps with overall yield of 24% with seven longest linear steps. In the penultimate step, dienoic acid 13 and a

Total synthesis of Carpatamides A–D

A synthetic strategy was developed for the synthesis of the common core structure of Carpatamides A–D. The total synthesis of Carpatamides A and C was completed in 6 steps and of Carpatamides B and D in 7 steps, by employing the Wittig olefination, olefin

Contrast agents for myocardial perfusion imaging

The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.